Table 2. Summary of follow-up time, surgery and trastuzumab treatment.
| Overall | NCT | NCAT | p | |
|---|---|---|---|---|
| Follow-up | 53.7 (41.7, 68.8) | 44.8 (37.0, 53.9) | 61.5 (50.3, 78.5) | |
| Time to first traz | 6.04 (3.52, 8.71) | 3.45 (2.96, 4.04) | 8.38 (6.64, 9.63) | <0.001 |
| Time to surgery | 5.72 (5.22, 6.44) | 5.95 (5.35, 6.77) | 5.52 (5.03, 6.21) | 0.012 |
| Trastuzumab Status: | ||||
| Completed | 185 (78.4) | 78 (80.0) | 107 (77.5) | |
| Ongoing | 13 (5.5) | 11 (11.2) | 2 (1.5) | |
| Stopped | 38 (16.1) | 9 (9.2) | 29 (21.0) | <0.001 |
| Reason for stopping: | ||||
| Cardiotoxicity | 15 (39.5) | 3 (33.3) | 12 (41.4) | |
| Patient's decision | 2 (5.3) | 1 (11.1) | 1 (3.5) | |
| Relapse | 15 (39.5) | 4 (44.4) | 11 (37.9) | |
| Other | 3 (7.9) | 1 (11.1) | 2 (6.9) | |
| Unknown | 3 (7.9) | 0 | 3 (10.3) | 0.712 |
| Number of Trastuzumab cycles: | 18 (1–36) | 18 (2–36) | 18 (1–20) | 0.8623 |